TipRanks (Thu, 11-Dec 6:16 AM ET)
AI adopters trade gaining steam; top stocks in AI adoption sectors
Seeking Alpha News (Tue, 9-Dec 4:28 AM ET)
Market Chameleon (Mon, 8-Dec 3:49 AM ET)
PRNewswire (Sat, 6-Dec 10:40 PM ET)
Business Wire (Wed, 3-Dec 8:00 AM ET)
Nuvation Bio Announces Participation in Two Major Healthcare Investor Conferences
Market Chameleon (Fri, 28-Nov 3:17 AM ET)
Nuvation Bio to Participate in Upcoming Investor Conferences
Business Wire (Wed, 26-Nov 4:05 PM ET)
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Business Wire (Mon, 3-Nov 4:05 PM ET)
Business Wire (Thu, 23-Oct 7:30 AM ET)
Business Wire (Mon, 20-Oct 4:05 PM ET)
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Nuvation Bio Class A trades on the NYSE stock market under the symbol NUVB.
As of December 12, 2025, NUVB stock price climbed to $8.54 with 2,565,344 million shares trading.
NUVB has a beta of 1.30, meaning it tends to be more sensitive to market movements. NUVB has a correlation of 0.06 to the broad based SPY ETF.
NUVB has a market cap of $2.92 billion. This is considered a Mid Cap stock.
Last quarter Nuvation Bio Class A reported $13 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $6 million and met earnings estimates .
In the last 3 years, NUVB traded as high as $8.95 and as low as $.95.
The top ETF exchange traded funds that NUVB belongs to (by Net Assets): IWM, VTI, IWN, IBB, VXF.
NUVB has outperformed the market in the last year with a price return of +218.7% while the SPY ETF gained +13.7%. NUVB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +154.9% and +6.6%, respectively, while the SPY returned +4.2% and +0.6%, respectively.
NUVB support price is $7.79 and resistance is $8.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUVB shares will trade within this expected range on the day.
